New PMN310 data presented in London show measurable drops in cerebrospinal fluid amyloid-beta oligomers at three and 29 …
New PMN310 data presented in London show measurable drops in cerebrospinal fluid amyloid-beta oligomers at three and 29 …
Efanesoctocog alfa’s extended half-life offers Australian patients a substantially reduced infusion burden compared with existing factor VIII replacement …
Gene-edited cell therapy exagamglogene autotemcel extends to pediatric patients as young as two, based on trial data showing …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
The donor-derived cell therapy is designed to be infused alongside a stem cell transplant, aiming to reduce a …
The bispecific antibody paired with lenalidomide showed a statistically significant improvement over standard care in patients with relapsed …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
Global biopharmaceutical mergers and acquisitions have surged to $106 billion across 201 transactions in 2026, putting the sector …
Early results from a multi-centre trial indicate that BI-8721 may slow cognitive decline and reduce amyloid biomarkers in …
Dual GLP-1 and GIP receptor agonist VK2735 moves into pivotal trials targeting robust weight loss and glycemic control …
Already a subscriber? Log in